Ligand Revenues Aided by Kyprolis and 4 Must-See Stock Analyses

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): According to Piper Jaffray, the GALNS data reported by BioMarin this morning supports FDA approval along with providing visibility into $750 million in sales. Piper stated that it continues to be a buyer of BioMarin shares into the company’s analyst meeting during November and the Phase II BMN-701 data release during Q1 of 2013, which the firm claims has the possibility of being the BioMarin’s biggest drug with its peak sales surpassing $1 billion for Pompe’s disease.

Ligand Pharmaceuticals Incorpor (NASDAQ:LGND): Onyx (NASDAQ:ONXX) reported $18.6 million in Kyprolis sales for Q3, and Roth Capital has mentioned that Ligand receives a 3 percennt average royalty on Kyprolis sales. The firm predicts that Kyprolis will assist Ligand in quickly becoming profitable, and it keeps its Buy rating and a $25 target on the stock.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Workday, Inc. (NYSE:WDAY) announced that Expedia’s (NASDAQ:EXPE) TripAdvisor deployed Workday Financial Management. TripAdvisor leveraged the unified financial management applications enabling it to show more visibility into operations, greater agility to respond to rapid growth, along with improved insights and analysis to deliver more value back to the business.

Penn Virginia Corp. (NYSE:PVA) price target has been reduced by Brean Capital due to its recent stock offerings, but it keeps its Buy rating based on cash flow and risk/reward.

Moog (NYSE:MOGA): According to Cowwen, Moog continues to be a little publicized story, and the firm views the shares as attractive due to  its cash flow, valuation relative to peers, and its positioned for earnings acceleration. Shares have an Outperform rating.

Don’t Miss: More Jobs But Higher Unemployment Rate: What Does This Mean for Obama?